Skip to main content
. 2021 Apr 13;6(16):10645–10654. doi: 10.1021/acsomega.0c06288

Figure 2.

Figure 2

(A) MCF-7/DOXFluc cells treated by DOX and Ber with different ratios for 48 h. n = 6, x̅ ± s. * P < 0.05, ** P < 0.01 vs the DOX group; #P < 0.05, ##P < 0.01 vs the Ber group. (B) Synergistic index curve of MCF-7/DOXFluc cells treated by DOX and Ber in different ratios for 48 h. (C) Tumor volumes of MCF-7/DOXFluc tumor-bearing nude mice treated by DOX (5 mg/kg, i.v.) alone or in combination with Ber (10 mg/kg, i.p.). * P < 0.05, ** P < 0.01 vs the PBS group; #P < 0.05, ##P < 0.01 vs the DOX group. a: PBS group; b: Ber group; c: DOX group; d: Ber + DOX group. (D) Visual observations of MCF-7/DOXFluc tumor volumes in each treatment group at the end time point. (E) BLIrel signal photon–time curve of MCF-7/DOXFluc treated in vivo by different drugs after intraperitoneally injecting d-luciferin potassium salt at a dose of 10 mg/kg. (F) Effect of different drugs on the body weight of MCF-7/DOXFluc tumor-bearing nude mice. * P < 0.05, ** P < 0.01 vs the PBS group. Significant differences were assessed using one-way ANOVA. Multiple comparisons between the groups were performed using the Tukey method. Results are presented as means ± SD.